Mast cells are typically linked to immediate hypersensitivity and anaphylaxis. This review looks beyond this narrow role, focusing on how these cells have evolved and diversified via natural selection promoting serine protease gene duplication, augmenting their innate host defense function against helminths and snake envenomation. Plasticity of mast cell genes has come at a price. Somatic activating mutations in the mast cell growth factor KIT gene cause cutaneous mastocytosis in young children and systemic mastocytosis with a more guarded prognosis in adults who may also harbor other gene mutations with oncogenic potential as they age. Allelic 
| FOREWORD
Scientists and clinicians alike recognize allergen-induced, IgEdependent mast cell (MC) degranulation leading to immediate hypersensitivity reactions and anaphylaxis as the sine qua non of MC dysfunction. This aspect of MC dysfunction has been extensively explored in previous original research articles and reviews and will not be covered here. The aim of this review was to summarize our current knowledge of primary and secondary MC disorders focusing on those not associated with acute allergic reactions, thus providing the reader with a broader and more complete understanding of the role of this immune cell in health and disease. It also aims to highlight how an appreciation of MC dysfunction from early infancy to old age can improve our understanding of this broad and complex range of disorders. Diversification of MC function coincided with extensive duplication of tryptase and other serine protease genes. 1 Gene duplication resulting in archetypal membrane-bound proteases being secreted into the milieu led to their systemic effects and may have been promoted by a survival advantage, with secreted MC proteases rapidly degrading and neutralizing potentially deadly Hymenoptera and snake toxins.
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Mast cells first evolved 500 million years ago in Ascidians (sea squirts), providing host innate immunity against bacteria and parasites. 4 Over the millennia, MCs gained additional functions regulating inflammation, wound healing, coagulation, adaptive immunity, and acute allergic responses. 5, 6 MCs are non-proliferating long-lived sedentary immune tissue cells. They differentiate from common myeloid precursors (CMPs) in the bone marrow. Immature MC precursors (MCp) with proliferative potential leave the bone marrow to home in on epithelial tissues in contact with the external environment such as the skin, respiratory and gastrointestinal tracts via specific integrin, and chemokine receptors (Figures 1 and 2 ). [7] [8] [9] [10] They also lodge in perivascular spaces and connective tissues surrounding nerves and then terminally differentiate into non-proliferating mature MCs expressing secretory granules. Inflammatory cytokines such as IL-4 can alter the balance of MC T and MC TC in the lungs, leading to a predominance of MC TC in asthmatics. [16] [17] [18] These observations suggest a degree of plasticity and interconversion between these two MC subtypes depending on the microenvironment ( Figure 2 The clinical course ranges from indolent to malignant (acute or chronic MC leukemia, MC sarcoma). 36 Adults with Hymenoptera venom anaphylaxis should also be investigated for systemic mastocytosis, even if baseline MC tryptase is normal and there are no skin signs. 37 The reported prevalence of underlying clonal mast cell disease in venom allergy varies greatly from 7% to 94%, but is higher in patients suffering from hypotension and syncope, 37, 38 and also in adults suffering from anaphylactic reactions after discontinuation of immunotherapy. The latter observation suggests that these patients may require lifelong venom immunotherapy. 39 is associated with a more stable clinical course and better prognosis. 43 Serum MC tryptase is usually >200 ng/mL. Response to radiotherapy and chemotherapy is usually transient and the prognosis is poor with median survival of less than 2 years. Chemotherapy combined with midostaurin (a multi-tyrosine kinase inhibitor) and followed by hematopoietic stem cell transplantation may be curative, but due to the rarity of these cancers, definitive data on the efficacy of this approach are limited. The pathogenesis and clinical disease spectrum of systemic mastocytosis parallel sporadic JAK2V617F gain of function mutations known to drive adult-onset myeloproliferative disorders. 44 
Systemic mastocytosis with activating KIT mutations in bone marrow
MCs is rare in children.
Children usually present with cutaneous rather than systemic mastocytosis (CM). Up to ninety percent have benign MC aggregates due to somatic KIT mutations confined to the skin. 45, 46 The common D816V is only found in 34%-42% of cases. In one study, an additional 44% of patients had gene mutations outside exon 17.
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Seventy-five percent have multiple brown skin patches. In a quarter, the rash is noticed at birth and in 90% by the age of 2 years old. [48] [49] [50] [51] Patches urticate on rubbing or bathing (urticaria pigmentosa) (Figure 4 ). CM can also present as one or more circumscribed reddish skin lesions (mastocytoma, 20%) or as a diffuse rash (5% 4.7 ng/mL) than healthy controls and patients with mild disease (2.5-3.1 ng/mL). 82 MC tryptase is more likely to be high in certain subgroups of asthmatics: older, obese patients, and non-atopic females with salicylate sensitivity. 83 Serum MC tryptase was also significantly higher in post-mortem lung from individuals who died of asthma (58-120 ng/mL) compared with those dying from other causes. 84, 85 In 2017, a RDBPCT of 62 adults with severe, poorly controlled asthma despite high-dose inhaled or systemic corticosteroids showed that imatinib led to a significant reduction in not only serum MC tryptase but also methacholine airway responsiveness. 86 Although the patients in this trial were not selected for their allergic predisposition, they had an mean on three positive skin prick test results. Overall, the current evidence indicates that MCs may well be important in severe allergic asthma and that drugs inhibiting MC activity can be beneficial.
| Chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is associated with frequent, often daily urticaria for 6 weeks or more. Symptoms often continue for many months or even years. Episodes of angioedema occur in half of cases. Unlike acute urticaria, specific IgE tests are not recommended in these patients. Symptomatic treatment of CSU is with a regular second-or third-generation antihistamine. Where these fail, omalizumab may be considered. Recent evidence suggests that complete responders have significantly higher serum total IgE concentrations than non-responders, suggesting that IgE-dependent MC degranulation may play a role in CSU. 87, 88 In 20% of patients, there is a clear physical trigger, such as pressure, temperature changes, or sun exposure. 89 CSU is usually sporadic and the underlying pathogenesis unknown, but in a rare autosomal dominant form triggered by vibration and rubbing of the skin, activating mutations in the dermatan sulfate-binding ADGRE2 cell surface receptor on MC promotes MC degranulation with physical forces. 106 On the other, in murine models of myocardial infarction and myocarditis, MCs have been shown to improve rather than worsen cardiac contractility. 107, 108 There is also evidence for the role of MCs in disrupting the integrity of blood vessels in the brain leading to saccular intracranial artery aneurysms, 109 and also the aorta resulting in abdominal aortic aneurysms. In a mouse model, MC tryptase MCP6 −/− mice or treatment with MC inhibitors prevented the development of aneurysms. 27 ,110,111 MC-deficient rats showed reduction of tPA-mediated cerebral hemorrhage compared with wild-type littermates. 112 It will be interesting to study the prevalence of these vascular diseases in patients with inherently higher MC tryptase concentrations, such as those with α-tryptasemia.
| Hypoxic-ischemic encephalopathy
Animal studies have shown infiltration of MCs and histamine release in the brain after hypoxic-ischemic insults in neonatal rats. 113 
| Sudden infant death syndrome
Serum MC tryptase has been found to be elevated in SIDS in some studies and it has been suggested that anaphylaxis may have a role in the pathogenesis of this syndrome in some patients. [117] [118] [119] In one study of 50 infants with SIDS, mean serum MC tryptase was 6.2 ng/ mL compared with 1.1 ng/mL in controls. 120 Forty percent of SIDS cases had MCT >10 ng/mL compared with none of the controls. In contrast, Nishio et al (2004) found that MC tryptase was normal in 21 infants with SIDS and 14 controls. 121 Genetic testing for KIT and TPSAB1 mutations in these patients might provide further insights into the pathogenesis of this disease. There is no doubt that MC infiltrate and degranulate in the tissues of patients with IBD and asthma, but the relevance of this to clinical disease remains unclear. There are, however, clues that as with eosinophilia, which is now deemed clinically relevant and effective suppressed with mepolizumab in a subset of severe asthmatics, 124 dampening down MC activity using imatinib in patients with refractory asthma is showing some promise.
| CONCLUSIONS
Finally, studies of animal models of common neonatal diseases of the lungs, eye, and brain suggest that MC may well have an important role in their pathogenesis. Although it is important to remain cautious when translating finding from animals into human, these results should provide the impetus to look for new solutions to these diseases with high healthcare burdens. 125 
